X

Drug Profile

ADVM 082

Alternative Names: ADVM-082

Latest Information Update: 09 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Adverum Biotechnologies
Developer Adverum Biotechnologies; Blue Gen Therapeutics Foundation
Class Eye disorder therapies; Gene therapies
Mechanism of Action CNGB3 protein replacements; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Colour vision defects

Most Recent Events

03 Sep 2024 ADVM 082 is available for licensing as of 03 Sep 2024. https://adverum.com/about-us/
29 Feb 2024 Preclinical trials in Colour vision defects in USA (Intravitreous)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com